We are live on
!
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$633M
1-Year Est. Return
173.22%
This Fund
S&P 500
This Quarter
Est. Return
-3.35%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$9.68M
(+9%)
Cap. Flow
+$18.7M
Cap. Flow
% of AUM
15.94%
Top 10 Holdings %
Top 10 Hldgs %
99.1%
Holding
15
New
1
Increased
9
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$9.14M |
| 2 |
Immunic
IMUX
|
+$7.08M |
| 3 |
PVLA
Palvella Therapeutics
PVLA
|
+$4.76M |
| 4 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$3.81M |
| 5 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$3.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travere Therapeutics
TVTX
|
+$10.6M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$7.35M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$164K |
| 4 |
ELEV
Elevation Oncology
ELEV
|
+$25K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLU
1
DELISTED
BELLUS Health Inc.
BLU
| $26.2M | 22.29% |
2,831,588
-20,000
| -0.7% | -$164K |
|
|
MRUS
2
DELISTED
Merus
MRUS
| $22.7M | 19.31% |
1,001,217
+107,690
| +12% | +$2.25M |
|
|
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $21.1M | 17.99% |
1,674,677
+982,169
| +142% | +$9.14M |
|
|
ALPN
4
DELISTED
Alpine Immune Sciences Inc
ALPN
| $16.4M | 13.97% |
1,926,869
+442,176
| +30% | +$3.81M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $7.64M | 6.51% |
2,589,679
+1,201,174
| +87% | +$2.87M |
|
|
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $6.69M | 5.7% |
2,180,560
+537,726
| +33% | +$3.28M |
|
|
PVLA
7
Palvella Therapeutics
PVLA
$1.98B
| $6.03M | 5.14% |
40,292
+26,088
| +184% | +$4.76M |
|
|
8
Immunic
IMUX
$182M
| $3.83M | 3.26% |
+110,424
| New | +$7.08M |
|
|
JBIO
9
Jade Biosciences
JBIO
$1.22B
| $2.99M | 2.55% |
5,473
+3,559
| +186% | +$1.7M |
|
|
THRX
10
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $2.79M | 2.38% |
504,862
+148,035
| +41% | +$1.22M |
|
11
Passage Bio
PASG
$15.9M
| $995K | 0.85% |
21,071
+15,796
| +299% | +$738K |
|
|
OTIC
12
DELISTED
Otonomy, Inc.
OTIC
| $62K | 0.05% |
30,000
| – | – |
|
|
ELEV
13
DELISTED
Elevation Oncology
ELEV
| – | – |
-10,000
| Closed | -$25K |
|
|
14
Travere Therapeutics
TVTX
$5.33B
| – | – |
-411,680
| Closed | -$10.6M |
|
|
IMGN
15
DELISTED
Immunogen Inc
IMGN
| – | – |
-1,543,259
| Closed | -$7.35M |
|
Similar funds
SWM
RFA
WA
AMM
EIM
SWP
ACM
BI
Lynx1 Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Lynx1 Capital Management held 15 positions worth $117M, up 9% from $108M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Lynx1 Capital Management deployed $18.7M of net new capital in Q2 2022, opening 1 new position and adding to 9 existing holdings. Its largest new stake was Immunic: 110,424 shares worth $3.83M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was BELLUS Health Inc., an estimated $164K trimmed.
- Lynx1 Capital Management's largest Q2 2022 buy was Immunic: 110,424 shares worth $3.83M.
- Lynx1 Capital Management added most to Kinnate Biopharma Inc. Common Stock in Q2 2022, an estimated $9.14M increase.
- Lynx1 Capital Management's biggest Q2 2022 reduction was BELLUS Health Inc., cutting an estimated $164K.
- Lynx1 Capital Management fully exited Travere Therapeutics in Q2 2022, selling an estimated $10.6M.
- Lynx1 Capital Management's ten largest holdings make up 99% of its $117M portfolio in Q2 2022.
- Lynx1 Capital Management opened 1 new position and closed 3 in Q2 2022.
- Lynx1 Capital Management's portfolio value rose 9% quarter-over-quarter to $117M.
Based on Lynx1 Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.